Giuseppe Realdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giuseppe Realdi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Nicola Vitturi
3 shared publications- Rocco Orlando
Department of Medical and Surgical Sciences; University of Padua Medical School; Padova Italy
2 shared publications D. Criscuolo
Prodotti Roche SpA, Milan, Italy
1 shared publicationD. Maladorno
Prodotti Roche SpA, Milan, Italy
1 shared publicationEmanouel Maragkoudakis
Institute of Internal Medicine
1 shared publicationF. Noventa
Istituto di Medicina Clinica, Clinica Medica 2, University of Padua, Padua, Italy
1 shared publication
Latest Publications
- 9 May 2017
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 12 (6) , 873-875
At the origin of medical semeiotics: the stethoscopy and the tactile vocal fremitus—still valuable tools at the bedside examination?
- 9 May 2017
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 12 (6) , 873-875
At the origin of medical semeiotics: the stethoscopy and the tactile vocal fremitus—still valuable tools at the bedside examination?
- 19 October 2011
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 6 (S1) , 85-92
Diagnostic pathways of the complex patients: rapid intensive observation in an Acute Medical Unit
The present-day patients have complex diseases that are responsible for the great increase of medical interventions, overcrowding in emergency departments and access to the wards, increased waiting times and length of stay, difficult discharge, increased readmission rate and finally increased mortality. By breaking the steps of the patients pathways it allows us to simplify the problems and to face the individual aspects of the complexity related to the management of patients in the hospital. One solution that has been growing in popularity is the rapid intensive observation of the patients in acute hospital setting within Internal Medicine wards. This model has been otherwise defined with different terminology, but the most widely used name is Acute Medical Unit (AMU). We describe the model of an AMU within an Internal Medicine department as proposed and adopted in Anglo-Saxon countries, the methods of clinical approach and the practical organisation of the units in close collaboration with the ED ward. Finally we report our experience at an Internal Medicine department in Padova and the initial results obtained during the first 4 months of the project. Our approach of intensive rapid observation of intermediate risk patients admitted from the ED led to a significant reduction in the duration of hospitalization, without increasing readmission rate after discharge and fatality rate. Factors significantly associated to a short hospital stay were a preserved function and a lower number of previous admissions to the hospital. Several gray zones in the realisation and management of the project were identified and the possible solutions are still matter of discussion and debate.
- 19 October 2011
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 6 (S1) , 85-92
Diagnostic pathways of the complex patients: rapid intensive observation in an Acute Medical Unit
The present-day patients have complex diseases that are responsible for the great increase of medical interventions, overcrowding in emergency departments and access to the wards, increased waiting times and length of stay, difficult discharge, increased readmission rate and finally increased mortality. By breaking the steps of the patients pathways it allows us to simplify the problems and to face the individual aspects of the complexity related to the management of patients in the hospital. One solution that has been growing in popularity is the rapid intensive observation of the patients in acute hospital setting within Internal Medicine wards. This model has been otherwise defined with different terminology, but the most widely used name is Acute Medical Unit (AMU). We describe the model of an AMU within an Internal Medicine department as proposed and adopted in Anglo-Saxon countries, the methods of clinical approach and the practical organisation of the units in close collaboration with the ED ward. Finally we report our experience at an Internal Medicine department in Padova and the initial results obtained during the first 4 months of the project. Our approach of intensive rapid observation of intermediate risk patients admitted from the ED led to a significant reduction in the duration of hospitalization, without increasing readmission rate after discharge and fatality rate. Factors significantly associated to a short hospital stay were a preserved function and a lower number of previous admissions to the hospital. Several gray zones in the realisation and management of the project were identified and the possible solutions are still matter of discussion and debate.
- 1 June 2010
- Vol. 19 (2) , 220-1
Paravaterian diverticula presenting as acute cholangitis in two very elderly patients.
- 1 June 2010
- Vol. 19 (2) , 220-1
Paravaterian diverticula presenting as acute cholangitis in two very elderly patients.
- 1 March 2009
- Vol. 18 (1) , 61-6
Perihepatic adipose tissue thickness: a new non-invasive marker of NAFLD?
Several non-invasive markers have been proposed to assess liver damage in NAFLD. We measured by ultrasound (US) the perihepatic adipose tissue thickness (PATT), i.e. the thickness of the fat between the abdominal muscular layer and the hepatic surface, in addition to waist circumference, BMI, biochemistry and serum adipokines, to predict the severity of liver damage in NAFLD. 63 NAFLD patients and 45 controls were studied. PATT and US steatosis score were assessed in all patients. Histology was obtained in those with an US steatosis score greater or equal to 2. PATT was 13.5 + or - 4.1 mm in NAFLD vs 8.0 + or - 4.1 in controls (p less than 0.001). A PATT value of 11.2 mm seems to represent a cut-off below which NAFLD is unlikely. Test sensitivity, specificity and the area under the ROC curve were 100%, 50% and 75%, respectively, suggesting a good discrimination between patients with non-NASH and those with NASH or borderline NASH. In addition, PATT strongly correlated with waist circumference (p less than 0.001). Both PATT and waist circumference correlated with US steatosis, HOMA-IR, TNF-alpha, IL-6 and leptin. Based on a multiple logistic regression analysis, waist circumferences greater or equal to 110, 113 and 122 cm were associated with a probability over or equal to 50% of abnormal HOMA-IR, TNF-alpha and leptin values, respectively. PATT and waist circumference could represent non-invasive markers predicting the severity of liver damage in NAFLD.
- 1 March 2009
- Vol. 18 (1) , 61-6
Perihepatic adipose tissue thickness: a new non-invasive marker of NAFLD?
Several non-invasive markers have been proposed to assess liver damage in NAFLD. We measured by ultrasound (US) the perihepatic adipose tissue thickness (PATT), i.e. the thickness of the fat between the abdominal muscular layer and the hepatic surface, in addition to waist circumference, BMI, biochemistry and serum adipokines, to predict the severity of liver damage in NAFLD. 63 NAFLD patients and 45 controls were studied. PATT and US steatosis score were assessed in all patients. Histology was obtained in those with an US steatosis score greater or equal to 2. PATT was 13.5 + or - 4.1 mm in NAFLD vs 8.0 + or - 4.1 in controls (p less than 0.001). A PATT value of 11.2 mm seems to represent a cut-off below which NAFLD is unlikely. Test sensitivity, specificity and the area under the ROC curve were 100%, 50% and 75%, respectively, suggesting a good discrimination between patients with non-NASH and those with NASH or borderline NASH. In addition, PATT strongly correlated with waist circumference (p less than 0.001). Both PATT and waist circumference correlated with US steatosis, HOMA-IR, TNF-alpha, IL-6 and leptin. Based on a multiple logistic regression analysis, waist circumferences greater or equal to 110, 113 and 122 cm were associated with a probability over or equal to 50% of abnormal HOMA-IR, TNF-alpha and leptin values, respectively. PATT and waist circumference could represent non-invasive markers predicting the severity of liver damage in NAFLD.
- 1 July 2008
- Published by Elsevier in Clinica Chimica Acta
- Vol. 393 (1) , 37-43
Selection of diagnostic tests for clinical decision making and translation to a problem oriented medical record
- 1 July 2008
- Published by Elsevier in Clinica Chimica Acta
- Vol. 393 (1) , 37-43
Selection of diagnostic tests for clinical decision making and translation to a problem oriented medical record
- 9 November 2004
- Vol. 19 (3) , 214-29
[Fever of unknown origin and monoclonal gammapathy with unclear significance. Report of 2 cases with different pathology and clinical course].
- 9 November 2004
- Vol. 19 (3) , 214-29
[Fever of unknown origin and monoclonal gammapathy with unclear significance. Report of 2 cases with different pathology and clinical course].
- 24 May 2004
- Published by Wiley in Helicobacter
- Vol. 9 (3) , 228-232
Novel Monoclonal Antibody‐Based Helicobacter pylori Stool Antigen Test
A number of noninvasive tests have been developed to establish the presence of Helicobacter pylori infection. Although polyclonal antibody-based stool antigen testing has a good sensitivity and specificity, it is less accurate than urea breath testing. Recently, a monoclonal antibody-based stool antigen test demonstrated an excellent performance in diagnosing H. pylori infection in adults and in pediatric populations. To evaluate the diagnostic accuracy of a novel stool test based on monoclonal antibodies to detect H. pylori antigens in frozen human stool in the pretreatment setting. Stool specimens were prospectively collected from 78 patients undergoing gastroscopy and stored at -20 degrees C until tested. Helicobacter pylori infection was evaluated by histology, rapid urease testing and urea breath tests ((13)C-UBT). Positivity of the three tests was considered the gold standard for H. pylori active infection. Patients with no positive test were considered negative. The gold standard was compare to the results of the monoclonal antibody stool antigen test. Frozen stool specimens were tested using a novel monoclonal-antibody-based enzyme immunoassay (HePy-Stool, Biolife-Italiana, Milan, Italy). The sensitivity and specificity of the monoclonal stool antigen test were 97%[95% confidence interval, (CI) 86-100] and 94% (95% CI: 81-99), respectively. Negative and positive predictive values were 97% (95% CI: 85-99), and 95% (95% CI: 83-99), respectively. The diagnostic accuracy was 96% (95% CI: 88-99). The likelihood ratio for a positive test was 17 and for a negative test was 0. Although the (13)C-UBT is the most accurate among the available noninvasive tests, our results show that an H. pylori stool test using monoclonal antibody might be an excellent alternative.
- 24 May 2004
- Published by Wiley in Helicobacter
- Vol. 9 (3) , 228-232
Novel Monoclonal Antibody‐Based Helicobacter pylori Stool Antigen Test
A number of noninvasive tests have been developed to establish the presence of Helicobacter pylori infection. Although polyclonal antibody-based stool antigen testing has a good sensitivity and specificity, it is less accurate than urea breath testing. Recently, a monoclonal antibody-based stool antigen test demonstrated an excellent performance in diagnosing H. pylori infection in adults and in pediatric populations. To evaluate the diagnostic accuracy of a novel stool test based on monoclonal antibodies to detect H. pylori antigens in frozen human stool in the pretreatment setting. Stool specimens were prospectively collected from 78 patients undergoing gastroscopy and stored at -20 degrees C until tested. Helicobacter pylori infection was evaluated by histology, rapid urease testing and urea breath tests ((13)C-UBT). Positivity of the three tests was considered the gold standard for H. pylori active infection. Patients with no positive test were considered negative. The gold standard was compare to the results of the monoclonal antibody stool antigen test. Frozen stool specimens were tested using a novel monoclonal-antibody-based enzyme immunoassay (HePy-Stool, Biolife-Italiana, Milan, Italy). The sensitivity and specificity of the monoclonal stool antigen test were 97%[95% confidence interval, (CI) 86-100] and 94% (95% CI: 81-99), respectively. Negative and positive predictive values were 97% (95% CI: 85-99), and 95% (95% CI: 83-99), respectively. The diagnostic accuracy was 96% (95% CI: 88-99). The likelihood ratio for a positive test was 17 and for a negative test was 0. Although the (13)C-UBT is the most accurate among the available noninvasive tests, our results show that an H. pylori stool test using monoclonal antibody might be an excellent alternative.
- 1 January 1990
- Published by Elsevier in Journal of Hepatology
- Vol. 11, S129-S132
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study
- 1 January 1990
- Published by Elsevier in Journal of Hepatology
- Vol. 11, S129-S132
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study